Considering the key role of increased thrombin generation (factor IIa) and tissue factor (TF) pathway activation in COVID-19-associated thrombosis [21], those features of tinzaparin abet the hypothesis for tinzaparin to have an extended role, interfering not only with coagulation cascade but also exhibiting anti-inflammatory potency in treatment and prophylaxis for COVID-19 patients [68]. This evidence concerns the gene F3 and Venous thrombosis.